Tao Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tao Zhao has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Haikun Zhang
School of Anesthesiology, Shandong Second Medical University, Weifang, China
8 shared publicationsJinxiang Yu
School of Anesthesiology, Shandong Second Medical University, Weifang, China
8 shared publicationsLe Cao
7 shared publicationsLifeng Jia
6 shared publicationsPengcheng Ma
6 shared publicationsJianhang You
School of Clinical Medicine, Shandong Second Medical University
5 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Delayed mechanical mitral prosthetic leaflet detachment with distal embolization and conservative management: a case report
- 19 September 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Open AccessDelayed mechanical mitral prosthetic leaflet detachment with distal embolization and conservative management: a case report
- Open Access
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 803
The landscape of protein post-translational modifications in the pathogenesis of acute respiratory distress syndrome
Acute respiratory distress syndrome (ARDS) remains one of the most severe forms of acute lung injury, characterized by diffuse alveolar damage and refractory hypoxemia secondary to non-cardiogenic pulmonary edema. After many years of research and incremental improvements in ventilatory and supportive strategies, mortality rates are still disappointingly high and no pharmacological agent has convincingly demonstrated a mortality benefit in large trials. Elucidating the rapid molecular processes driving the acute phase of lung injury, particularly post-translational modifications (PTMs), may be critical for devising targeted therapies and potentially lowering mortality. In this review, we provide a comprehensive synthesis of the multifaceted roles of PTMs in ARDS pathogenesis, bridging molecular mechanisms to clinical relevance. We begin by examining canonical modifications, including phosphorylation and ubiquitination, which serve as swift molecular switches coordinating the cytokine storm, endothelial barrier disruption, and defective alveolar fluid clearance. We then discuss emerging PTMs, including citrullination, lactylation, and succinylation, and highlight their contributions to neutrophil extracellular trap (NET) formation and inflammatory amplification. We examine how metabolic reprogramming of the ARDS lung directly governs PTM enzyme activity and substrate availability, thereby acting as an upstream regulatory layer linking cellular metabolism to PTM dynamics. We further discuss how PTMs do not operate independently but engage in obligatory sequential and competitive crosstalk. Finally, we explore the therapeutic promise of modulating specific PTM-regulating enzymes alongside precision medicine approaches, underscoring the value of multi-omics integration in surmounting current translational barriers against this deadly syndrome.
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 803
Open AccessThe landscape of protein post-translational modifications in the pathogenesis of acute respiratory distress syndrome
Acute respiratory distress syndrome (ARDS) remains one of the most severe forms of acute lung injury, characterized by diffuse alveolar damage and refractory hypoxemia secondary to non-cardiogenic pulmonary edema. After many years of research and incremental improvements in ventilatory and supportive strategies, mortality rates are still disappointingly high and no pharmacological agent has convincingly demonstrated a mortality benefit in large trials. Elucidating the rapid molecular processes driving the acute phase of lung injury, particularly post-translational modifications (PTMs), may be critical for devising targeted therapies and potentially lowering mortality. In this review, we provide a comprehensive synthesis of the multifaceted roles of PTMs in ARDS pathogenesis, bridging molecular mechanisms to clinical relevance. We begin by examining canonical modifications, including phosphorylation and ubiquitination, which serve as swift molecular switches coordinating the cytokine storm, endothelial barrier disruption, and defective alveolar fluid clearance. We then discuss emerging PTMs, including citrullination, lactylation, and succinylation, and highlight their contributions to neutrophil extracellular trap (NET) formation and inflammatory amplification. We examine how metabolic reprogramming of the ARDS lung directly governs PTM enzyme activity and substrate availability, thereby acting as an upstream regulatory layer linking cellular metabolism to PTM dynamics. We further discuss how PTMs do not operate independently but engage in obligatory sequential and competitive crosstalk. Finally, we explore the therapeutic promise of modulating specific PTM-regulating enzymes alongside precision medicine approaches, underscoring the value of multi-omics integration in surmounting current translational barriers against this deadly syndrome.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (6) , 665
Integrative single-cell and bulk transcriptomic analyses identify IGFBP2 within a peri-anesthetic stress-related gene framework linked to injury/transitional remodeling of alveolar type II cells in idiopathic pulmonary fibrosis
In idiopathic pulmonary fibrosis (IPF), damage to alveolar type II (AT2) cells and their aberrant reprogramming are regarded as key events in disease progression. Apart from anesthetic exposure, the peri-anesthetic period is also characterized by additional stressors, such as mechanical ventilation-induced stretch. Here, peri-anesthetic stress-related genes (PSRGs) were treated as a literature-derived, biologically relevant prior gene framework to prioritize candidate genes associated with AT2 state remodeling in IPF. Single-cell and bulk transcriptomic datasets from IPF and control lungs were analyzed. PSRGs were intersected with concordant differentially expressed genes to identify candidate hub genes, which were further prioritized using an integrated machine-learning framework. IGFBP2 expression in AT2-related states was analyzed in GSE128033 and validated in GSE135893, with complementary pseudo-bulk, correlation, covariate, CellChat, scTenifoldKnk, and DrugCLIP analyses. Two AT2 states, mature and injury/transitional, were identified. IGFBP2 was prioritized for state-focused analysis and showed reproducible enrichment in injury/transitional AT2 cells in both GSE128033 and GSE135893. IGFBP2 expression also increased along pseudotime, whereas COL1A1 did not show a clear trajectory-related pattern. Cell-cell communication analysis suggested prominent microenvironmental interactions involving injury/transitional AT2 cells. Computational perturbation analysis further implicated epithelial secretory and mucosal defense-related programs within the IGFBP2-associated network. IGFBP2 was identified as a reproducibly enriched candidate in injury/transitional AT2 cells across discovery and validation cohorts. These findings suggest that IGFBP2 may be associated with AT2 state remodeling and altered epithelial microenvironmental communication in IPF, although functional and protein level validation remains necessary.
- 1 June 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (6) , 665
Open AccessIntegrative single-cell and bulk transcriptomic analyses identify IGFBP2 within a peri-anesthetic stress-related gene framework linked to injury/transitional remodeling of alveolar type II cells in idiopathic pulmonary fibrosis
In idiopathic pulmonary fibrosis (IPF), damage to alveolar type II (AT2) cells and their aberrant reprogramming are regarded as key events in disease progression. Apart from anesthetic exposure, the peri-anesthetic period is also characterized by additional stressors, such as mechanical ventilation-induced stretch. Here, peri-anesthetic stress-related genes (PSRGs) were treated as a literature-derived, biologically relevant prior gene framework to prioritize candidate genes associated with AT2 state remodeling in IPF. Single-cell and bulk transcriptomic datasets from IPF and control lungs were analyzed. PSRGs were intersected with concordant differentially expressed genes to identify candidate hub genes, which were further prioritized using an integrated machine-learning framework. IGFBP2 expression in AT2-related states was analyzed in GSE128033 and validated in GSE135893, with complementary pseudo-bulk, correlation, covariate, CellChat, scTenifoldKnk, and DrugCLIP analyses. Two AT2 states, mature and injury/transitional, were identified. IGFBP2 was prioritized for state-focused analysis and showed reproducible enrichment in injury/transitional AT2 cells in both GSE128033 and GSE135893. IGFBP2 expression also increased along pseudotime, whereas COL1A1 did not show a clear trajectory-related pattern. Cell-cell communication analysis suggested prominent microenvironmental interactions involving injury/transitional AT2 cells. Computational perturbation analysis further implicated epithelial secretory and mucosal defense-related programs within the IGFBP2-associated network. IGFBP2 was identified as a reproducibly enriched candidate in injury/transitional AT2 cells across discovery and validation cohorts. These findings suggest that IGFBP2 may be associated with AT2 state remodeling and altered epithelial microenvironmental communication in IPF, although functional and protein level validation remains necessary.
- Open Access
- 5 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1786697
Fibroblast transformation in the tumor microenvironment of lung adenocarcinoma: heterogeneity, regulation, and therapeutic targeting
Cancer-associated fibroblasts (CAFs) are important stromal cells in the tumor microenvironment of lung adenocarcinoma (LUAD). This review discusses the different cellular sources of CAFs and the main signaling pathways involved in fibroblast-to-CAF transition, with attention to the biological settings that are especially relevant in LUAD. It further discusses CAF heterogeneity not only in terms of functional subtypes, but also from the perspective of dynamic cell states shaped by spatial niche, intercellular communication, and therapy-related stress. On this basis, we outline how distinct CAF states contribute to extracellular matrix remodeling, metabolic reprogramming, invasion and metastasis, angiogenesis, immunosuppression, and therapeutic resistance in LUAD. Particular attention is given to the treatment relevance of CAFs in driver-defined disease settings, where stromal programs may influence responses to targeted therapy and immunotherapy in a context-dependent manner. We also address the main obstacles to CAF-targeted strategies, particularly heterogeneity, plasticity, and functional compensation, and point to possible directions based on precise subtyping, functional modulation, and rational combination therapy. This review thus offers a LUAD-specific perspective for understanding CAF biology and for guiding more precise stromal intervention strategies.
- 5 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1786697
Open AccessFibroblast transformation in the tumor microenvironment of lung adenocarcinoma: heterogeneity, regulation, and therapeutic targeting
Cancer-associated fibroblasts (CAFs) are important stromal cells in the tumor microenvironment of lung adenocarcinoma (LUAD). This review discusses the different cellular sources of CAFs and the main signaling pathways involved in fibroblast-to-CAF transition, with attention to the biological settings that are especially relevant in LUAD. It further discusses CAF heterogeneity not only in terms of functional subtypes, but also from the perspective of dynamic cell states shaped by spatial niche, intercellular communication, and therapy-related stress. On this basis, we outline how distinct CAF states contribute to extracellular matrix remodeling, metabolic reprogramming, invasion and metastasis, angiogenesis, immunosuppression, and therapeutic resistance in LUAD. Particular attention is given to the treatment relevance of CAFs in driver-defined disease settings, where stromal programs may influence responses to targeted therapy and immunotherapy in a context-dependent manner. We also address the main obstacles to CAF-targeted strategies, particularly heterogeneity, plasticity, and functional compensation, and point to possible directions based on precise subtyping, functional modulation, and rational combination therapy. This review thus offers a LUAD-specific perspective for understanding CAF biology and for guiding more precise stromal intervention strategies.
- 16 April 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (4) , 475-499
Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure
Regorafenib, a multi-kinase inhibitor, has demonstrated clinical efficacy in various malignancies, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), and gastrointestinal stromal tumors (GISTs). However, the emergence of resistance significantly limits its long-term therapeutic benefits. Rather than representing isolated molecular events, regorafenib resistance can be conceptualized as a dynamic process of “adaptive network collapse and rewiring”. Owing to its broad inhibition of angiogenic, stromal, and tumor-intrinsic kinases, regorafenib induces an initial collapse of signaling networks, which subsequently drives compensatory rewiring through receptor tyrosine kinase (RTK) bypass activation, cytokine-mediated feedback, and transcriptional reprogramming. Within this framework, resistance mechanisms can be hierarchically organized into drug-proximal adaptive signaling (VEGFR-associated pathways and RTK bypass), network-level regulatory processes (epigenetic modulation, drug transporters, and cancer stemness), and downstream phenotypic adaptations, including metabolic reprogramming, epithelial–mesenchymal transition (EMT), autophagy, and tumor microenvironment remodeling. These processes function in a coordinated manner to restore network robustness under sustained pharmacological pressure. Importantly, this integrative perspective provides a rationale for therapeutic intervention. While downstream adaptations may contribute to resistance maintenance, targeting key nodes of network rewiring—such as EGFR, STAT3, and microenvironmental signaling pathways—may offer more effective and durable strategies. Accordingly, combination approaches integrating regorafenib with targeted agents, immune checkpoint inhibitors (ICIs), metabolic modulators, or emerging therapeutic platforms are discussed. Overall, this review provides a systems-level understanding of regorafenib resistance and highlights the importance of mechanism-guided combination therapies and biomarker-driven strategies to improve clinical outcomes.
- 16 April 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (4) , 475-499
Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure
Regorafenib, a multi-kinase inhibitor, has demonstrated clinical efficacy in various malignancies, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), and gastrointestinal stromal tumors (GISTs). However, the emergence of resistance significantly limits its long-term therapeutic benefits. Rather than representing isolated molecular events, regorafenib resistance can be conceptualized as a dynamic process of “adaptive network collapse and rewiring”. Owing to its broad inhibition of angiogenic, stromal, and tumor-intrinsic kinases, regorafenib induces an initial collapse of signaling networks, which subsequently drives compensatory rewiring through receptor tyrosine kinase (RTK) bypass activation, cytokine-mediated feedback, and transcriptional reprogramming. Within this framework, resistance mechanisms can be hierarchically organized into drug-proximal adaptive signaling (VEGFR-associated pathways and RTK bypass), network-level regulatory processes (epigenetic modulation, drug transporters, and cancer stemness), and downstream phenotypic adaptations, including metabolic reprogramming, epithelial–mesenchymal transition (EMT), autophagy, and tumor microenvironment remodeling. These processes function in a coordinated manner to restore network robustness under sustained pharmacological pressure. Importantly, this integrative perspective provides a rationale for therapeutic intervention. While downstream adaptations may contribute to resistance maintenance, targeting key nodes of network rewiring—such as EGFR, STAT3, and microenvironmental signaling pathways—may offer more effective and durable strategies. Accordingly, combination approaches integrating regorafenib with targeted agents, immune checkpoint inhibitors (ICIs), metabolic modulators, or emerging therapeutic platforms are discussed. Overall, this review provides a systems-level understanding of regorafenib resistance and highlights the importance of mechanism-guided combination therapies and biomarker-driven strategies to improve clinical outcomes.
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (5) , e47370
Ferroptosis in glaucoma: Identification of key genes NR1D2 and AKR1C3 based on transcriptome bioinformatics analysis
Glaucoma, a leading cause of blindness, involves retinal ganglion cell death linked to ferroptosis, an iron-dependent form of cell death. This study analyzed GEO datasets (GSE9944 and GSE2378) to identify ferroptosis-related genes in glaucoma. Least absolute shrinkage and selection operator and support vector machine-recursive feature elimination methods were used to select key genes, and bioinformatics tools were applied to assess their diagnostic potential and biological significance. NR1D2 and AKR1C3 were identified as key ferroptosis-related genes with high diagnostic potential. These genes are involved in redox reactions, cellular processes, and immune responses. Drug sensitivity and competitive endogenous RNA network analyses further confirmed their value as potential diagnostic biomarkers and therapeutic targets. NR1D2 and AKR1C3 are promising biomarkers for diagnosing glaucoma and serve as potential therapeutic targets, offering new insights into its pathogenesis and treatment strategies.
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (5) , e47370
Open AccessFerroptosis in glaucoma: Identification of key genes NR1D2 and AKR1C3 based on transcriptome bioinformatics analysis
Glaucoma, a leading cause of blindness, involves retinal ganglion cell death linked to ferroptosis, an iron-dependent form of cell death. This study analyzed GEO datasets (GSE9944 and GSE2378) to identify ferroptosis-related genes in glaucoma. Least absolute shrinkage and selection operator and support vector machine-recursive feature elimination methods were used to select key genes, and bioinformatics tools were applied to assess their diagnostic potential and biological significance. NR1D2 and AKR1C3 were identified as key ferroptosis-related genes with high diagnostic potential. These genes are involved in redox reactions, cellular processes, and immune responses. Drug sensitivity and competitive endogenous RNA network analyses further confirmed their value as potential diagnostic biomarkers and therapeutic targets. NR1D2 and AKR1C3 are promising biomarkers for diagnosing glaucoma and serve as potential therapeutic targets, offering new insights into its pathogenesis and treatment strategies.
- 6 January 2026
- Published by Elsevier in Brain Research
- Vol. 1874, 150153
Identification of the disulfidptosis-related gene IQGAP1 as a potential diagnostic biomarker in Parkinson’s disease
- 6 January 2026
- Published by Elsevier in Brain Research
- Vol. 1874, 150153
Identification of the disulfidptosis-related gene IQGAP1 as a potential diagnostic biomarker in Parkinson’s disease
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Emodin Attenuates LPS‐Induced Acute Lung Injury Through Suppression of the LCK/Fyn/AKT/p38 Signaling Axis: Integrated Transcriptomic and Experimental Evidence
Background: Sepsis‐associated acute lung injury (ALI) is characterized by intense inflammatory signaling and epithelial injury, yet effective pathway‐directed therapies remain limited. Emodin has anti‐inflammatory and tissue‐protective properties, but the signaling mechanisms relevant to inflammatory lung injury are not fully defined. Methods: Sepsis‐associated genes were identified in GSE65682 by differential expression analysis and weighted gene co‐expression network analysis (WGCNA). Candidate emodin‐associated targets were integrated with the sepsis gene set and examined by protein–protein interaction analysis, functional enrichment, four machine‐learning models, and single‐cell RNA sequencing of GSE167363. Key predictions were then evaluated in an LPS‐induced ALI mouse model and in LPS‐stimulated A549 cells. Results: We identified 318 sepsis‐associated genes and 34 candidate therapeutic targets. LCK , MAPK14 , and FYN were central network nodes; internally cross‐validated models showed near‐perfect discrimination but were interpreted as exploratory, and single‐cell analysis localized TSPO and UPP1 mainly to myeloid populations. In mice, emodin improved lung histopathology and reduced the inflammation score without a monotonic dose response; TNF‐α was broadly reduced, IL‐6 responses were dose selective, and IL‐1β showed no consistent change. In A549 cells, emodin was noncytotoxic, reduced LPS‐induced caspase‐3 activity, and lowered EdU positivity at low and medium doses. Emodin also reduced selected candidate‐gene transcripts and LCK/Fyn/AKT/p38 phosphorylation. MAPK14 silencing decreased p38 protein and the LPS‐associated inflammation score. Conclusions: Emodin attenuated LPS‐induced inflammatory lung injury and cellular stress in association with reduced LCK/Fyn/AKT/p38 signaling. The findings support a contributory role for MAPK14 /p38, while direct target engagement and the translational relevance of computationally prioritized candidates require independent validation.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessEmodin Attenuates LPS‐Induced Acute Lung Injury Through Suppression of the LCK/Fyn/AKT/p38 Signaling Axis: Integrated Transcriptomic and Experimental Evidence
Background: Sepsis‐associated acute lung injury (ALI) is characterized by intense inflammatory signaling and epithelial injury, yet effective pathway‐directed therapies remain limited. Emodin has anti‐inflammatory and tissue‐protective properties, but the signaling mechanisms relevant to inflammatory lung injury are not fully defined. Methods: Sepsis‐associated genes were identified in GSE65682 by differential expression analysis and weighted gene co‐expression network analysis (WGCNA). Candidate emodin‐associated targets were integrated with the sepsis gene set and examined by protein–protein interaction analysis, functional enrichment, four machine‐learning models, and single‐cell RNA sequencing of GSE167363. Key predictions were then evaluated in an LPS‐induced ALI mouse model and in LPS‐stimulated A549 cells. Results: We identified 318 sepsis‐associated genes and 34 candidate therapeutic targets. LCK , MAPK14 , and FYN were central network nodes; internally cross‐validated models showed near‐perfect discrimination but were interpreted as exploratory, and single‐cell analysis localized TSPO and UPP1 mainly to myeloid populations. In mice, emodin improved lung histopathology and reduced the inflammation score without a monotonic dose response; TNF‐α was broadly reduced, IL‐6 responses were dose selective, and IL‐1β showed no consistent change. In A549 cells, emodin was noncytotoxic, reduced LPS‐induced caspase‐3 activity, and lowered EdU positivity at low and medium doses. Emodin also reduced selected candidate‐gene transcripts and LCK/Fyn/AKT/p38 phosphorylation. MAPK14 silencing decreased p38 protein and the LPS‐associated inflammation score. Conclusions: Emodin attenuated LPS‐induced inflammatory lung injury and cellular stress in association with reduced LCK/Fyn/AKT/p38 signaling. The findings support a contributory role for MAPK14 /p38, while direct target engagement and the translational relevance of computationally prioritized candidates require independent validation.